These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 9644703

  • 1. Octreotide in the management of diarrhea induced by graft versus host disease.
    Ippoliti C, Neumann J.
    Oncol Nurs Forum; 1998 Jun; 25(5):873-8. PubMed ID: 9644703
    [Abstract] [Full Text] [Related]

  • 2. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.
    Ippoliti C, Champlin R, Bugazia N, Przepiorka D, Neumann J, Giralt S, Khouri I, Gajewski J.
    J Clin Oncol; 1997 Nov; 15(11):3350-4. PubMed ID: 9363865
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation.
    Morton AJ, Durrant ST.
    Clin Transplant; 1995 Jun; 9(3 Pt 1):205-8. PubMed ID: 7549062
    [Abstract] [Full Text] [Related]

  • 4. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
    Topkan E, Karaoglu A.
    Oncology; 2006 Jun; 71(5-6):354-60. PubMed ID: 17873499
    [Abstract] [Full Text] [Related]

  • 5. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
    Pai V, Porter K, Ranalli M.
    Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
    [Abstract] [Full Text] [Related]

  • 6. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.
    Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB.
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):101-7. PubMed ID: 15682070
    [Abstract] [Full Text] [Related]

  • 7. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
    Mystakidou K, Katsouda E, Tsilika E, Smyrniotis V, Vassiliou I, Tsiatas M, Vlahos L.
    Anticancer Res; 2006 Feb; 26(3B):2325-8. PubMed ID: 16821610
    [Abstract] [Full Text] [Related]

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 9. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease.
    Ely P, Dunitz J, Rogosheske J, Weisdorf D.
    Am J Med; 1991 Jun; 90(6):707-10. PubMed ID: 2042686
    [Abstract] [Full Text] [Related]

  • 10. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA.
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [Abstract] [Full Text] [Related]

  • 11. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery.
    Gullichsen R.
    Tech Coloproctol; 2006 Dec; 10(4):346-9. PubMed ID: 17115310
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
    Rosenoff SH, Gabrail NY, Conklin R, Hohneker JA, Berg WJ, Warsi G, Maloney J, Benedetto JJ, Miles EA, Zhu W, Anthony L.
    J Support Oncol; 2006 Jun; 4(6):289-94. PubMed ID: 16805331
    [Abstract] [Full Text] [Related]

  • 13. Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea.
    Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou V, Kalofonos HP.
    Oncologist; 1998 Jun; 3(1):50-53. PubMed ID: 10388084
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S.
    Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
    [Abstract] [Full Text] [Related]

  • 15. Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child.
    Beckman RA, Siden R, Yanik GA, Levine JE.
    J Pediatr Hematol Oncol; 2000 Apr; 22(4):344-50. PubMed ID: 10959906
    [Abstract] [Full Text] [Related]

  • 16. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study.
    Akpek G, Chinratanalab W, Lee LA, Torbenson M, Hallick JP, Anders V, Vogelsang GB.
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):46-51. PubMed ID: 12533741
    [Abstract] [Full Text] [Related]

  • 17. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation.
    Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA.
    Bone Marrow Transplant; 2004 Jun; 33(11):1131-5. PubMed ID: 15094743
    [Abstract] [Full Text] [Related]

  • 18. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR.
    Cancer; 2002 May 01; 94(9):2409-15. PubMed ID: 12015766
    [Abstract] [Full Text] [Related]

  • 20. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G, Beguin Y.
    Br J Haematol; 2000 Dec 01; 111(3):745-53. PubMed ID: 11122133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.